ViroPharma says company well positioned for future acquisitions

By Jennifer Lanning Drey

Portland, Ore., June 18 - ViroPharma Inc. believes its current cash balance positions the company well for downstream business development opportunities, including potential future acquisitions currently being suppressed by market conditions, William Roberts, ViroPharma's vice president of corporate communications, said Thursday at the Jefferies & Co. Healthcare Conference in New York.

ViroPharma had $245 million of cash and cash equivalents at March 31.

The company is currently focused on the launch of Cinryze, which is has been on the market for about six months for prevention of hereditary angioedema.

The company believes there is significant possibility for upside related to the drug, including expanding its application to other diseases, adding territories outside of the United States and developing additional formulations, Roberts said.

ViroPharma is an Exton, Pa., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.